Last update: Oct. 9, 2016
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Inhibitor of 5-α reductase enzyme that induces the pass of testosterone to dihydrotestosterone which has a greater androgenic effect.
Indicated for treatment of benign prostatic hypertrophy.
Not authorized for use in women although it is used for treatment of hirsutism with same or greater efficacy than Spironolactone or Flutamide (Moghetti 2000), androgenetic alopecia (Shum 2002) and Polycystic Ovary Syndrome (Lakryc 2003) .
At latest update no published data on excretion into breast milk were found.
Its high plasma protein-binding capacity makes it unlikely the excretion of significant amounts into breastmilk.
Not alterations on prolactin level have been reported.
A known and safer alternative should be preferred until more published data on this drug related to breastfeeding is available within the first 6 mo after birth, especially during the neonatal period and in case of prematurity.
Exposure through breastmilk may be minimized by waiting at least 6 hours before resuming breastfeed after the last dose of drug.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM